CasInvent
2 known investors
CasInvent Pharma is a Masaryk University spin-off developing proprietary, highly selective small-molecule inhibitors of the Casein Kinase 1 (CK1) family to treat therapy-resistant tumors. Its candidate compounds target indications such as acute myeloid leukemia, melanoma, triple-negative breast cancer, pancreatic cancer, and prostate cancer, and are being advanced through preclinical toward clinical development.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does CasInvent do?
- CasInvent Pharma is a Masaryk University spin-off developing proprietary, highly selective small-molecule inhibitors of the Casein Kinase 1 (CK1) family to treat therapy-resistant tumors. Its candidate compounds target indications such as acute myeloid leukemia, melanoma, triple-negative breast cancer, pancreatic cancer, and prostate cancer, and are being advanced through preclinical toward clinical development.
- Who are CasInvent's investors?
- CasInvent's investors include Biotech Investments S.R.O, JIC Ventures.